|
Re: Toxicity
|
2
|
Zenith Epigenetics
|
Nov 02, 2022 03:53PM
|
|
Re: Two big thank you’s
|
2
|
Zenith Epigenetics
|
Nov 24, 2022 03:49PM
|
|
Re: National Research Council's financially supported companies for COVID and LONG COVID
|
2
|
Resverlogix Corp.
|
Dec 09, 2022 01:37PM
|
|
Re: Two big thank you’s
|
2
|
Zenith Epigenetics
|
Nov 24, 2022 07:55PM
|
|
Re: Apabetalone inhibits kidney damage in diabetes
|
2
|
Resverlogix Corp.
|
Aug 23, 2024 12:13PM
|
|
Re: Your thoughts please
|
2
|
Resverlogix Corp.
|
Sep 09, 2024 11:53AM
|
|
Re: Two big thank you’s
|
2
|
Zenith Epigenetics
|
Nov 25, 2022 12:40PM
|
|
Re: debenture
|
2
|
Resverlogix Corp.
|
Mar 20, 2023 12:05PM
|
|
Re: Zenith Royalties
|
2
|
Resverlogix Corp.
|
Jun 27, 2023 05:10PM
|
|
Re: Another Week
|
2
|
Resverlogix Corp.
|
Oct 21, 2022 04:08PM
|
|
Re: Resverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients
|
2
|
Resverlogix Corp.
|
Jun 13, 2023 12:32PM
|
|
Link to 2023 AGM presentation is up
|
2
|
Resverlogix Corp.
|
Jun 21, 2023 01:22PM
|
|
Re: OTC Expert & Grey Market Restrictions
|
2
|
Zenith Epigenetics
|
Nov 22, 2022 02:05PM
|
|
Re: OTC Expert & Grey Market Restrictions
|
2
|
Zenith Epigenetics
|
Nov 22, 2022 03:12PM
|
|
Re: Random thoughts in the vacuum of information
|
2
|
Resverlogix Corp.
|
Jul 03, 2024 03:36PM
|
|
Re: Zenith Epigenetics Reports Advancement of ZEN-3694 in NUT Carcinoma
|
2
|
Zenith Epigenetics
|
Jun 01, 2023 07:24PM
|
|
Re: Report Of Exempt Distribution.
|
2
|
Zenith Epigenetics
|
Apr 17, 2024 07:10PM
|
|
Re: A Special Meeting of Shareholders?
|
2
|
Resverlogix Corp.
|
May 30, 2024 04:35PM
|
|
Re: Change in Auditors
|
1
|
Resverlogix Corp.
|
Mar 12, 2023 05:05PM
|
|
Re: Lu stepping down
|
1
|
Resverlogix Corp.
|
Feb 22, 2024 02:24PM
|
